Advancing the Development of Novel Targets, Safe, & Effective Multi-Specific Immune Cell Engagers for Solid & Liquid Tumors in the Clinic 

Next Event in the Series

Welcome to the 6th Cell Engager Summit!

Prioritizing Back Translation from Bedside to Bench & Novel Targets

With a whopping 7 approvals in the last two years, the field is alive with positive clinical read outs and the drive to get more life changing cell engager therapeutics to patients in indications of huge unmet need.

The timely 6th Cell Engager Therapeutics Summit is back once again to meet the needs of the community, focused on reaching new indications by expanding the target space and focusing our content to novel targets as well as continuing the push to focus on the translational challenges of developing cell engager therapies for solid and liquid tumours.

Join 100+ of your colleagues from JNJ, Astellas, Amgen, CDR-Life, Regeneron, Immunocore, Crossbow Therapeutics and AstraZeneca in discovery and translational sciences, learn from clinical case studies to back translate, improve engineering by tuning affinity via adapting engager format and mitigating cytokine release syndrome. This is your one stop shop for all of the must have content dedicated to all engagers such as T-cell engagers, BiTe’s, gamma delta engagers and NK engagers.

As we look to prioritize the next generation intracellular targets, how you go about validating, discovering, and creating the next therapies to target them, the power of cell engager technology is clear. Overcome your key challenges in developing cell engagers across three days of highly focused content - don’t miss out!

2024 World Class Speakers Includes:

Companies Who Attended:

“Plenty of opportunities for networking. Very friendly and casual atmosphere that facilitates engaging with colleagues” – Principal Scientific Researcher, Genentech

genentech logo

“Open discussion about current challenges in the cell engager space” – Director, Abcellera